Stand Up To Cancer (SU2C), in partnership with the American Association for Cancer Research, is inviting Letters of Intent for a new $10 million "Dream Team" grant.
Unlike other "Dream Team" grant opportunities offered by SU2C in recent years, the SU2C Dream Team Translational Cancer Research Grant program is open to any type of translational cancer research. The program will support a single translational cancer research project that addresses a critical problem in patient care and has the potential to deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, expert team of investigators.
The proposed project may focus on a particular organ site, patient population (e.g., pediatrics), or innovative method of treatment. The project must be designed to accelerate the application of a new preventive, diagnostic, or therapeutic approach to the clinic that leads to patient involvement within two to three years from the beginning of the grant.
In addition, through collaboration with leading healthcare research and innovation center OptumLabs, the team will have the opportunity to gain access to and conduct research using OptumLabs' proprietary database of de-identified medical claims and electronic health record clinical data, analytic tools, and research.
To maximize creativity, innovation, and collaboration, the team of investigators must include laboratory and clinical researchers, senior and/or young investigators, and senior scientists who have not worked together in the past.
Letters of Intent must be received no later than September 5, 2017. Upon review, selected applicants will be invited to submit afull proposal by January 16, 2018.
See the SU2C website for complete program guidelines and application instructions.